Clinical Trial Update: A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia [Phase 2]

View source ↗

Summary

A Phase 2a trial update for HT-6184 in patients with IPSS-R very low/low/intermediate risk myelodysplastic syndromes and anemia, with the study currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia in Myelodysplastic Syndromes
• Myelodysplastic Syndromes

Drugs mentioned

• HT-6184

Snippet

Sponsor: Halia Therapeutics, Inc. | Conditions: Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes | Phase 2 | Status: ACTIVE_NOT_RECRUITING